v3.24.0.1
STOCK-BASED COMPENSATION (Tables)
12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of stock-based compensation expense
        
   Year Ended December 31, 
   2023   2022 
Research and development  $1,408   $1,153 
General and administrative   2,265    1,965 
Selling and Marketing   340    249 
Total  $4,013   $3,367 
Schedule of weighted-average assumptions
         
   Year Ended December 31, 
   2023   2022 
Exercise price:  $6.54   $14.21 
Grant date fair value per share:  $4.94   $10.37 
Assumptions:          
Expected volatility   82.59%    83.18% 
Weighted average expected term (in years)   6.82    6.51 
Risk-free interest rate   4.03%    1.96% 
Expected dividend yield   0.0%    0.0% 
Schedule of stock option activity
                
  

Number of

Shares

  

Weighted-

Average

Exercise

Prices

  

Weighted-Average

Remaining

Contractual

Term
(In Years)

   Intrinsic Value 
Outstanding at January 1, 2023   3,009   $7.07           
Granted   393   $6.54           
Exercised   (33)  $3.90           
Outstanding at December 31, 2023   3,369   $7.04    4.66   $3,437 
Exercisable at December 31, 2023   2,862   $6.64    3.95   $3,190 
Schedule of restricted stock activity
        
   Number of Shares   Weighted-Average Grant Date Fair Value 
Outstanding at January 1, 2023   340   $10.78 
Granted   357   $7.00 
Vested   (258)  $8.27 
Forfeited   (20)  $8.63 
Outstanding non-vested shares at December 31, 2023   419   $9.21